PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.68%
Revenue growth at 50-75% of 9843.T's 7.22%. Martin Whitman would worry about competitiveness or product relevance.
7.34%
Gross profit growth 1.25-1.5x 9843.T's 5.36%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
14.18%
EBIT growth above 1.5x 9843.T's 3.19%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
14.18%
Positive operating income growth while 9843.T is negative. John Neff might view this as a competitive edge in operations.
28.60%
Positive net income growth while 9843.T is negative. John Neff might see a big relative performance advantage.
28.61%
Positive EPS growth while 9843.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
28.61%
Positive diluted EPS growth while 9843.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
28.80%
10Y revenue/share CAGR under 50% of 9843.T's 123.11%. Michael Burry would suspect a lasting competitive disadvantage.
48.70%
5Y revenue/share CAGR similar to 9843.T's 51.26%. Walter Schloss might see both companies benefiting from the same mid-term trends.
22.33%
3Y revenue/share CAGR at 75-90% of 9843.T's 27.98%. Bill Ackman would expect new product strategies to close the gap.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.58%
Net income/share CAGR at 50-75% of 9843.T's 107.99%. Martin Whitman might question if the firm’s product or cost base lags behind.
18.88%
Below 50% of 9843.T's 66.85%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
12.08%
Below 50% of 9843.T's 29.14%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
161.83%
10Y equity/share CAGR at 50-75% of 9843.T's 307.04%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
104.73%
5Y equity/share CAGR 1.25-1.5x 9843.T's 83.15%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
50.85%
3Y equity/share CAGR 1.25-1.5x 9843.T's 45.67%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
81.82%
Below 50% of 9843.T's 255754.67%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
77.78%
Below 50% of 9843.T's 3400.00%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
45.45%
3Y dividend/share CAGR 1.25-1.5x 9843.T's 40.00%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
43.48%
Our AR growth while 9843.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
3.24%
Inventory shrinking or stable vs. 9843.T's 10.22%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
5.71%
Asset growth above 1.5x 9843.T's 1.48%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.66%
Similar to 9843.T's 3.37%. Walter Schloss finds parallel capital usage or profit distribution strategies.
111.10%
We have some new debt while 9843.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-40.01%
We cut SG&A while 9843.T invests at 7.91%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.